Skip Navigation


Rheumatology Advance Access originally published online on March 20, 2009
Rheumatology 2009 48(6):704; doi:10.1093/rheumatology/kep042
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/6/704    most recent
kep042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Müller-Ladner, U.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Müller-Ladner, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Unifying abbreviations for biologics in rheumatology—does the idea hold promise?

Ulf Müller-Ladner1,2

1Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Giessen and 2Department of Rheumatology and Clinical Immunology, Kerckhoff Clinic, Bad Nauheim, Germany

Correspondence to: Ulf Müller-Ladner, Department of Rheumatology and Clinical Immunology, Kerckhoff Clinic, Benekestrasse 2-8, D-61231 Bad Nauheim, Germany. E-mail: u.mueller-ladner@kerckhoff-klinik.de

The first 10% of the full text of this article appears below.

SIR, Since presenting the idea of a unifying abbreviation system for biologics used in trials and in clinics . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?